Search results
Showing 1 to 15 of 69 results for visual disturbance
YAG laser vitreolysis for symptomatic vitreous floaters (HTG644)
Evidence-based recommendations on YAG laser vitreolysis for symptomatic vitreous floaters. This involves a special type of laser (YAG) firing short pulses of energy into the floaters, to break them up (vitreolysis) and reduce sight disturbances.
View recommendations for HTG644Show all sections
Therapeutic endoscopic division of epidural adhesions (HTG210)
Evidence-based recommendations on therapeutic endoscopic division of epidural adhesions. This involves separating epidural adhesions from the nerves or spinal cord through a small cut near the lower spine (keyhole surgery).
View recommendations for HTG210Show all sections
Sections for HTG210
Ultrasound-guided foam sclerotherapy for varicose veins (HTG301)
Evidence-based recommendations on ultrasound guided foam sclerotherapy for varicose veins. This involves mixing a chemical with air or another gas to produce a foam, which is injected into the affected vein using ultrasound imaging to monitor its progress.
View recommendations for HTG301Show all sections
Sections for HTG301
Macular translocation with 360° retinotomy for wet age-related macular degeneration (HTG216)
Evidence-based recommendations on macular translocation with 360° retinotomy for wet age-related macular degeneration. This involves cutting and moving the macula on to a nearby healthier area of the choroid layer.
This guideline covers the diagnosis and management of tension-type headache, migraine (including migraine with aura and menstrual-related migraine), cluster headache and medication overuse headache in young people (aged 12 years and older) and adults. It aims to improve the recognition and management of headaches, with more targeted treatment to improve the quality of life for people with headaches, and to reduce unnecessary investigations.
Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)
Evidence-based recommendations on ranibizumab (Lucentis) for treating choroidal neovascularisation associated with pathological myopia in adults.
This quality standard covers decision making in people aged 16 and over, using health and social care services who may lack capacity to make their own decisions (now or in the future). It aims to support implementation of the aims and principles of the Mental Capacity Act 2005 and relevant Codes of Practice. It is not a substitute for these.
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)
Evidence-based recommendations on ranibizumab (Lucentis) and pegaptanib (Macugen) for treating wet age-related macular degeneration in adults.
Cerebral palsy in under 25s: assessment and management (NG62)
This guideline covers diagnosing, assessing and managing cerebral palsy in children and young people from birth up to their 25th birthday. It aims to make sure they get the care and treatment they need for the developmental and clinical comorbidities associated with cerebral palsy, so that they can be as active and independent as possible.
Delirium: prevention, diagnosis and management in hospital and long-term care (CG103)
This guideline covers diagnosing and treating delirium in people aged 18 and over in hospital and in long-term residential care or a nursing home. It also covers identifying people at risk of developing delirium in these settings and preventing onset. It aims to improve diagnosis of delirium and reduce hospital stays and complications.
Evidence-based recommendations on ranibizumab (Lucentis) for treating visual impairment caused by macular oedema secondary to retinal vein occlusion in adults.
This quality standard covers the prevention, diagnosis and management of delirium in adults (aged 18 and over) in hospital or long-term care settings (such as residential care or nursing homes). It describes high-quality care in priority areas for improvement.
View quality statements for QS63Show all sections
Sections for QS63
- Quality statements
- Quality statement 1: Assessing recent changes that may indicate delirium
- Quality statement 2: Interventions to prevent delirium
- Quality statement 3: Use of antipsychotic medication for people who are distressed
- Quality statement 4: Information and support
- Quality statement 5: Communication of diagnosis to GPs
- Update information
- About this quality standard
Evidence-based recommendations on lumbar subcutaneous shunt. This involves using a shunt to drain excess cerebrospinal fluid away so that it doesn’t damage the brain or eyes.
View recommendations for HTG41Show all sections
Sections for HTG41
MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy (HTG541)
Evidence-based recommendations on MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy in adults and children. This involves inserting a laser into the area of the brain causing seizures.
View recommendations for HTG541Show all sections
Trabecular stent bypass microsurgery for open-angle glaucoma (HTG432)
Evidence-based recommendations on trabecular stent bypass microsurgery for open-angle glaucoma. This involves inserting a hollow metal tube (stent) into the eye, to improve drainage of fluid from the eye.